Mechanisms of Hypercalcemia in non-Hodgkin Lymphoma and Associated Outcomes: a Retrospective Review

The etiology of hypercalcemia in non-Hodgkin lymphoma (NHL) is most often attributed to either elevated serum levels of 1,25-dihydroxycholecalciferol (calcitriol) or parathyroid-related protein (PTHrP). In a single center retrospective review we evaluated the incidence of and outcomes associated with hypercalcemia in NHL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. BarrAbstractBackgroundAs oral targeted agents, such as ibrutinib, become more widely used, understanding the impact of suboptimal dosing on overall survival (OS) and progression-free survival (PFS) outside of clinical trials is imperative.Patients and MethodsData on ibrutinib discontinuation, dose reductions, and treatment interruptions were collected on ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This review summarizes the more recent evidence about epidemiology and risk factors for invasive fungal infections (IFI) in patients affected by Chronic Lymphocytic Leukemia (CLL), indolent Non Hodgkin Lymphoma (iNHL) and Multiple Myeloma (MM).Despite advances in the prognosis and treatment of hematological malignancies in recent years, susceptibility to infection remains a significant challenge to patient care. A large amount of data regarding patients with acute leukemia has been published while little information is available on the incidence of IFI in chronic lymphoproliferative disorders (CLD).New drugs are now availa...
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Source Type: research
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): AnnaLynn M. Williams, Andrea Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. BarrAbstractBackgroundAs oral targeted agents, such as ibrutinib, become more widely used understanding the impact of suboptimal dosing on overall and progression-free survival outside of clinical trials is imperative.MethodsData on ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma (NHL) and chr...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractPurpose of the ReviewThis review summarizes data about epidemiology, treatment, and risk factors for invasive fungal infections (IFI) in patients affected by chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and indolent non Hodgkin lymphoma (iNHL).Recent FindingsDespite advances in the prognosis and treatment of hematological malignancies in recent years, susceptibility to infection remains a significant challenge to patient care. A large amount of data regarding patients with acute leukemias have been published while little information is available on incidence of IFI in chronic lymphoproliferative disor...
Source: Current Fungal Infection Reports - Category: Infectious Diseases Source Type: research
Orally administered targeted therapies, including ibrutinib, are increasingly used to treat non-Hodgkin lymphoma (NHL); however, little is known about the clinical impact of suboptimal dosing. Data on reasons and time frames for ibrutinib discontinuation, dose reductions, and treatment interruptions were collected on 170 NHL and chronic lymphocytic leukemia patients treated with ibrutinib at a single institution. Discontinuation of ibrutinib therapy and suboptimal dose adherence were associated with poor outcome.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Orally administered targeted therapies, including ibrutinib, are increasing used to treat non-Hodgkin lymphoma, however, little is known about the clinical impact of suboptimal dosing. Data on reasons and timeframes for ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma and chronic lymphocytic leukemia patients treated with ibrutinib at a single institution. Discontinuation of ibrutinib therapy was associated with poor outcome as previously reported. We also show that discontinuation of therapy for reasons other than progression and reduction of ibrutinib dose ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
ConclusionsForty percent of patients receiving DA-EPOCH-R therapy developed LACs, almost one-half of whom experienced grade 3 toxicities. The complication rate was significantly greater in patients undergoing therapy with DA-EPOCH-R compared with those undergoing R-CHOP therapy. Clinicians need to balance these risks when selecting therapy. Future studies are needed to evaluate prophylactic anticoagulation strategies in this population.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study reveals important areas of progress in cancer outcomes in Canada since the early 1990s. It also sheds light on cancers for which there has seemingly been no improvement in five-year net survival over a 20-year period. PMID: 30230521 [PubMed - in process]
Source: Health Reports - Category: International Medicine & Public Health Tags: Health Rep Source Type: research
Dysregulation of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins of the intrinsic apoptotic pathway is fundamental to the pathophysiology of many hematologic malignancies. The BCL-2 family consists of regulatory proteins that either induce apoptosis (proapoptotic) or inhibit it (prosurvival). BCL-2, myeloid cell leukemia-1, and B-cell lymphoma–extra large are prosurvival proteins that are prime targets for anticancer therapy, and molecules targeting each are in various stages of preclinical and clinical development. The US Food and Drug Administration (FDA)-approved BCL-2 inhibitor venetoclax was first prov...
Source: Blood - Category: Hematology Authors: Tags: Myeloid Neoplasia, Lymphoid Neoplasia, Review Articles Source Type: research
ConclusionsForty percent of patients receiving DA-EPOCH-R therapy developed LAC, almost half of whom experienced grade 3 toxicities. The complication rate was significantly greater in patients undergoing therapy with DA-EPOCH-R, compared to R-CHOP. Clinicians need to balance these risks when selecting therapy. Future studies are needed to evaluate prophylactic anticoagulation strategies in this population.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Study